WO2024069448 - SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME
National phase entry is expected:
Publication Number
WO/2024/069448
Publication Date
04.04.2024
International Application No.
PCT/IB2023/059571
International Filing Date
27.09.2023
Title **
[English]
SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME
[French]
COMPOSÉS DE 1-ARYLAMINOCARBONYL-1'-HÉTÉROARYLE SUBSTITUÉS, COMPOSÉS DE 1-HÉTÉROARYLAMINOCARBONYL-1'-HÉTÉROARYLE SUBSTITUÉS ET PROCÉDÉS LES UTILISANT
Applicants **
ARBUTUS BIOPHARMA CORPORATION
Inventors
COLE, Andrew G.
FAN, Yi
HEFFERNAN, Gavin D.
OZTURK, Seyma
QUINTERO, Jorge G.
Priority Data
63/410,766
28.09.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 10262 | |
| EPO | Filing, Examination, Granting | 62890 | |
| Japan | Filing, Examination, Granting | 3674 | |
| South Korea | Filing, Examination, Granting | 5087 | |
| USA | Filing, Examination, Granting | 23940 |
Total:
105,853
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure includes substituted 1-arylaminocarbonyl-1'-heteroaryl compounds, substituted 1-heteroarylaminocarbonyl-1'-heteroaryl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the disclosure can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a subject. In another aspect, the compounds contemplated in the disclosure can be used to treat, ameliorate, and/or prevent cancer in a subject.[French]
La présente invention concerne des composés dr 1-arylaminocarbonyl -1'-hétéroaryle substitués, des composés de 1-hétéroarylaminocarbonyl-1'-hétéroaryle substitués, des analogues de ceux-ci, et des compositions les comprenant. Selon un aspect, les composés envisagés dans l'invention peuvent être utilisés pour traiter, améliorer et/ou prévenir des infections par le virus de l'hépatite B (VHB) et/ou le virus de l'hépatite D (VHD) chez un sujet. Selon un autre aspect, les composés envisagés dans l'invention peuvent être utilisés pour traiter, faire régresser et/ou prévenir le cancer chez un sujet.